PMEF
CRL icon

Point72 Middle East FZE’s Charles River Laboratories CRL Stock Holding History

Point72 Middle East FZE’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-3,301
Closed -$719K – 1738
2022
Q4 		$719K Buy
+3,301
New +$721K 0.03% 591

Other funds holding CRL

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Kayne Anderson Rudnick Investment Management
Kayne Anderson Rudnick Investment Management Los Angeles, California $34B AUM 6.31% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $59.7B AUM 29.08% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
JSP
Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return

Point72 Middle East FZE's CRL Position: Q1 2023 in Review

Point72 Middle East FZE sold out of Charles River Laboratories (CRL) in Q1 2023, closing a stake of 3,301 shares — an estimated $719K sold.

Point72 Middle East FZE first reported a position in CRL in Q4 2022 and held it in 1 quarter. The position peaked at $719K in Q4 2022. 620 funds tracked by Wall St. Rank hold CRL as of Q1 2023.

  • Point72 Middle East FZE reported no remaining Charles River Laboratories position as of Q1 2023 after selling out during the quarter.
  • Point72 Middle East FZE sold 3,301 Charles River Laboratories shares in Q1 2023, an estimated $719K.
  • Point72 Middle East FZE first reported a position in Charles River Laboratories in Q4 2022 and held it in 1 quarter.
  • Point72 Middle East FZE's Charles River Laboratories position peaked at $719K in Q4 2022.
  • 620 funds tracked by Wall St. Rank held Charles River Laboratories as of Q1 2023.

Based on Point72 Middle East FZE's 13F filing for Q1 2023, filed 15 May 2023.